Research / Clinical Trials

Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials

In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3

In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF

In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩‍⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy

In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩‍⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch

NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials.

Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n

In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors